Nkarta (NKTX) Research & Development (2019 - 2026)
Nkarta's quarterly Research & Development came in at $25.0 million in Q1 2026, up 3.38% year-on-year from $24.2 million in Q1 2025, and down 1.16% quarter-over-quarter from $25.3 million in Q4 2025.
Nkarta has reported Research & Development for 8 years, with the latest figure at $25.0 million in Q1 2026.
- For the quarter ending Q1 2026, Research & Development rose 3.38% year-over-year to $25.0 million; the trailing twelve-month figure through Mar 2026 stood at $91.2 million (down 4.63% YoY), and the FY2025 full-year result was $90.4 million, down 6.53% from the prior year.
- Research & Development for Q1 2026 stood at $25.0 million, down from $25.3 million in the prior quarter.
- The five-year high for Research & Development was $26.8 million in Q4 2022, with the low at $19.6 million in Q1 2022.
- Average Research & Development over 5 years is $23.5 million, with a median of $23.4 million recorded in 2022.
- Year-over-year, Research & Development surged 55.16% in 2022 and declined 20.01% in 2025.
- Tracing NKTX's Research & Development over 5 years: stood at $26.8 million in 2022, then fell by 13.12% to $23.3 million in 2023, then declined by 0.84% to $23.1 million in 2024, then grew by 9.31% to $25.3 million in 2025, then declined by 1.16% to $25.0 million in 2026.
- The last three Research & Development figures came in at $25.0 million (Q1 2026), $25.3 million (Q4 2025), and $20.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Nkarta | 232.80 Mn | 232.80 Mn | - | 24.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24.99 Mn |
| Dec 31, 2025 | 25.28 Mn |
| Sep 30, 2025 | 20.20 Mn |
| Jun 30, 2025 | 20.78 Mn |
| Mar 31, 2025 | 24.17 Mn |
| Dec 31, 2024 | 23.13 Mn |
| Sep 30, 2024 | 25.25 Mn |
| Jun 30, 2024 | 23.13 Mn |
| Mar 31, 2024 | 25.24 Mn |
| Dec 31, 2023 | 23.32 Mn |
| Sep 30, 2023 | 22.19 Mn |
| Jun 30, 2023 | 25.12 Mn |
| Mar 31, 2023 | 26.14 Mn |
| Dec 31, 2022 | 26.84 Mn |
| Sep 30, 2022 | 23.44 Mn |
| Jun 30, 2022 | 21.05 Mn |
| Mar 31, 2022 | 19.57 Mn |
| Dec 31, 2021 | 17.30 Mn |
| Sep 30, 2021 | 16.62 Mn |
| Jun 30, 2021 | 15.96 Mn |
| Mar 31, 2021 | 13.54 Mn |
| Dec 31, 2020 | 11.27 Mn |
| Sep 30, 2020 | 9.83 Mn |
| Jun 30, 2020 | 7.86 Mn |
| Mar 31, 2020 | 7.26 Mn |
| Dec 31, 2019 | 6.68 Mn |
| Sep 30, 2019 | 4.62 Mn |
| Jun 30, 2019 | 3.62 Mn |